Related Experiment Video
Updated: Dec 10, 2025
Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours
Long Wang1, Gengyuan Zhang1, Long Qin2
1The First Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730000, Gansu Province, China.
Background:
Epidermal Growth Factor Receptor (EGFR) and members of its homologous protein family mediate transmembrane signal transduction by binding to a specific ligand, which leads to regulated cell growth, differentiation, proliferation and metastasis. With the development and application of Genetically Engineered Antibodies (GEAs), Nanobodies (Nbs) constitute a new research hot spot in many diseases. A Nb is characterized by its low molecular weight, deep tissue penetration, good solubility and high antigen-binding affinity, the anti-EGFR Nbs are of significance for the diagnosis and treatment of EGFR-positive tumours.
Objective:
This review aims to provide a comprehensive overview of the information about the molecular structure of EGFR and its transmembrane signal transduction mechanism, and discuss the anti-EGFR-Nbs influence on the diagnosis and treatment of solid tumours.
Methods:
Data were obtained from PubMed, Embase and Web of Science. All patents are searched from the following websites: the World Intellectual Property Organization (WIPO®), the United States Patent Trademark Office (USPTO®) and Google Patents.
Results:
EGFR is a key target for regulating transmembrane signaling. The anti-EGFR-Nbs for targeted drugs could effectively improve the diagnosis and treatment of solid tumours.
Conclusion:
EGFR plays a role in transmembrane signal transduction. The Nbs, especially anti- EGFR-Nbs, have shown effectiveness in the diagnosis and treatment of solid tumours. How to increase the affinity of Nb and reduce its immunogenicity remain a great challenge.
Insights
Anti-Epidermal Growth Factor Receptor (EGFR) Nanobodies (Nbs) show promise for treating EGFR-positive solid tumors by targeting transmembrane signaling. Further research is needed to enhance Nb affinity and reduce immunogenicity for optimal therapeutic use.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Epidermal Growth Factor Receptor (EGFR) is crucial for cell growth, differentiation, and metastasis.
- Genetically Engineered Antibodies (GEAs), specifically Nanobodies (Nbs), are emerging as potent tools in disease research.
- Anti-EGFR Nbs offer potential for diagnosing and treating EGFR-positive tumors due to their unique characteristics.
Purpose of the Study:
- To review the molecular structure and signal transduction of EGFR.
- To discuss the impact of anti-EGFR Nbs on the diagnosis and treatment of solid tumors.
Main Methods:
- Comprehensive literature search using PubMed, Embase, and Web of Science.
- Patent searches conducted via WIPO, USPTO, and Google Patents.
Main Results:
- EGFR is a key regulator of transmembrane signaling pathways.
- Anti-EGFR Nbs demonstrate potential for improving solid tumor diagnosis and treatment.
Conclusions:
- EGFR is integral to transmembrane signal transduction.
- Anti-EGFR Nbs show efficacy in solid tumor management.
- Enhancing Nb affinity and reducing immunogenicity are key challenges.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
